NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Forecast, Price & News

$1.14

-0.03 (-2.56%)

(As of 09/22/2023 ET)

Compare

Today's Range: $1.10
▼
$1.19
50-Day Range: $1.14
▼
$2.42
52-Week Range: $1.09
▼
$9.00

Volume: 432,572 shs
Average Volume: 413,879 shs
Market Capitalization: $82.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.50

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 1,259.6% Upside
$15.50 Price Target
Short Interest: Healthy
3.30% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.66
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.38) to ($1.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

201st out of 963 stocks

Pharmaceutical Preparations Industry

79th out of 458 stocks

3.2

Analyst's Opinion

Consensus Rating
Kezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.50, Kezar Life Sciences has a forecasted upside of 1,259.6% from its current price of $1.14.
Amount of Analyst Coverage
Kezar Life Sciences has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.30% of the outstanding shares of Kezar Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Kezar Life Sciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kezar Life Sciences has recently decreased by 2.83%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Kezar Life Sciences does not currently pay a dividend.
Dividend Growth
Kezar Life Sciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kezar Life Sciences has received a 73.01% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Kezar Life Sciences is -0.85.

3.1

News and Social Media Coverage

News Sentiment
Kezar Life Sciences has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.
Search Interest
3 people have searched for KZR on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.90% of the stock of Kezar Life Sciences is held by insiders.
Percentage Held by Institutions
86.83% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Kezar Life Sciences are expected to decrease in the coming year, from ($1.38) to ($1.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kezar Life Sciences is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kezar Life Sciences is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kezar Life Sciences has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

KZR Price History

30 days | 90 days | 365 days | Advanced Chart

KZR Stock News Headlines

September 21, 2023 | msn.com

Kezar and Everest enter lupus nephritis therapy development deal

September 20, 2023 | marketwatch.com

Kezar Life Sciences Shares Rise After Deal With Everest Medicines

September 24, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 20, 2023 | businesswire.com

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China ...

September 20, 2023 | finance.yahoo.com

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

August 14, 2023 | 247wallst.com

Wells Fargo Downgrades Kezar Life Sciences

August 12, 2023 | msn.com

Wells Fargo Downgrades Kezar Life Sciences (KZR)

August 11, 2023 | marketwatch.com

Kezar Life Sciences Down 25% After 2Q Results, Drug Updates

September 24, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

August 11, 2023 | finance.yahoo.com

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

June 23, 2023 | fool.com

Kezar Life Sciences (NASDAQ: KZR)

May 31, 2023 | finance.yahoo.com

Kezar Life Sciences to Participate in the Jefferies Healthcare Conference

May 13, 2023 | marketwatch.com

8-K: Kezar Life Sciences, Inc.

May 12, 2023 | msn.com

Wells Fargo Maintains Kezar Life Sciences (KZR) Overweight Recommendation

May 12, 2023 | msn.com

HC Wainwright & Co. Maintains Kezar Life Sciences (KZR) Buy Recommendation

May 12, 2023 | msn.com

Kezar Life Sciences: Q1 Earnings Insights

May 11, 2023 | seekingalpha.com

Kezar Life Sciences GAAP EPS of -$0.31

May 11, 2023 | finance.yahoo.com

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

March 16, 2023 | msn.com

William Blair Downgrades Kezar Life Sciences (KZR)

March 16, 2023 | seekingalpha.com

Kezar sheds 14% after R&D event as William Blair downgrades

March 14, 2023 | finance.yahoo.com

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

March 13, 2023 | finance.yahoo.com

Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

March 6, 2023 | finance.yahoo.com

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

March 1, 2023 | finance.yahoo.com

Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

February 23, 2023 | seekingalpha.com

KZR Kezar Life Sciences, Inc.

January 4, 2023 | finance.yahoo.com

Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023 | markets.businessinsider.com

Wells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)

See More Headlines

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Company Calendar

Last Earnings: 8/10/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KZR
CUSIP: N/A
CIK: 1645666
Web: www.kezarlifesciences.com
Phone: (650) 822-5600
Fax: N/A
Employees: 84
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.50
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +1,259.6%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,240,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -31.81%
Return on Assets: -28.66%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 17.73
Quick Ratio: 17.73

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.95 per share
Price / Book: 0.29

Miscellaneous

Outstanding Shares: 72,690,000
Free Float: 66,950,000
Market Cap: $82.87 million
Optionable: Not Optionable
Beta: 0.16

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. John Franklin Fowler (Age 50)
Co-Founder, CEO & Director
Comp: $919.91k

Dr. Christopher J. Kirk Ph.D. (Age 50)
Co-Founder & Director
Comp: $677.41k

Dr. Noreen Roth Henig M.D. (Age 58)
Chief Medical Officer
Comp: $722.85k

Dr. Jack Taunton Ph.D.
Co-Founder

Mr. Marc L. Belsky (Age 68)
CFO & Sec.

Ms. Gitanjali Jain
VP of Investor Relations & External Affairs

Mr. Mark Schiller
Sr. VP of Legal Affairs

Dr. Neel K. Anand Ph.D.
Sr. VP of Research & Drug Discovery

Dr. Nick Mordwinkin Ph.D. (Age 42)
Pharm.D., Chief Bus. Officer

Mr. Zung To
Sr. VP of Clinical Devel. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares.
View KZR analyst ratings or view top-rated stocks.
What is Kezar Life Sciences' stock price forecast for 2023?: 3 brokers have issued twelve-month target prices for Kezar Life Sciences' shares. Their KZR share price forecasts range from $13.00 to $18.00. On average, they expect the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,259.6% from the stock's current price.
View analysts price targets for KZR or view top-rated stocks among Wall Street analysts.
How have KZR shares performed in 2023?: Kezar Life Sciences' stock was trading at $7.04 at the beginning of the year. Since then, KZR shares have decreased by 83.8% and is now trading at $1.14.
View the best growth stocks for 2023 here.
When is Kezar Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our KZR earnings forecast.
How were Kezar Life Sciences' earnings last quarter?: Kezar Life Sciences, Inc. (NASDAQ:KZR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01.
What other stocks do shareholders of Kezar Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?: (KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.
What is Kezar Life Sciences' stock symbol?: Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."
Who are Kezar Life Sciences' major shareholders?: Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.86%), BlackRock Inc. (7.03%), Prosight Management LP (6.40%), Sphera Funds Management LTD. (2.74%), Granahan Investment Management LLC (2.61%) and Franklin Resources Inc. (1.92%). Insiders that own company stock include Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends.
How do I buy shares of Kezar Life Sciences?: Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kezar Life Sciences' stock price today?: One share of KZR stock can currently be purchased for approximately $1.14.
How much money does Kezar Life Sciences make?: Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $82.87 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.
How can I contact Kezar Life Sciences?: Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kezar Life Sciences (KZR) Stock Forecast, Price & News

Kezar Life Sciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Kezar Life Sciences (NASDAQ:KZR) Stock

KZR Price History

KZR Stock News Headlines

KZR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KZR Stock - Frequently Asked Questions

Overall MarketRank^™